Cellbricks Therapeutics Raises €10 Million in Seed Funding
Cellbricks Therapeutics has announced a successful seed funding round, securing €10 million to further its innovative work in the development of biofabricated human tissue implants. The funding round was led by Silicon Roundabout Ventures, with additional participation from the Federal Agency for Breakthrough Innovation and ACT Venture Partners.
Company Background
Based in Europe, Cellbricks Therapeutics focuses on creating biofabricated tissue implants designed to serve as biological alternatives to synthetic options. The company's technology primarily targets unmet needs in areas such as reconstructive surgery, wound healing, and trauma care. Their goal is to develop living, vascularized tissue implants that can eventually lead to viable human organ replacement.
Leadership Insights
Alexander Leutner, Co-CEO and Co-Founder of Cellbricks Therapeutics, emphasized the company's mission: "The ambition is clear: restoring functional human tissue and, ultimately, enabling organ replacement. This funding allows us to reach the next level of validation." Co-CEO Simon Mackenzie added, "The next chapter is about demonstrating what can actually work in relevant models."
Strategic Use of Funds
The newly acquired funds will be directed toward advancing the translational development of Cellbricks' living tissue implants. Immediate priorities include preclinical validation and progressing their lead adipose tissue implant program. The company also aims to initiate multiple preclinical animal studies. These efforts are foundational steps toward future human clinical studies.
Focus Areas
Cellbricks Therapeutics is keen on addressing complex soft tissue defects, with particular attention to applications in breast reconstruction. Their broader vision includes using 3D-bioprinting technology to create viable human organs, a step-by-step approach that begins with tissue-specific solutions capable of surviving and integrating within the human body.
This significant seed funding round marks a pivotal moment for Cellbricks Therapeutics as it continues to innovate in the field of regenerative medicine, moving closer to providing new solutions for patients in need of advanced tissue repair and replacement options.